1378388-20-5

Basic information

• Product Name: GS-5818 interMediate
• Synonyms: GS-5818 interMediate;3-Chloro-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one;3-chloro-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one;3-Chloro-10,11-dihydro-5H,9H-6-oxa-benzo[a]anthracen-8-one
• CAS NO: 1378388-20-5
• Molecular Formula: C₁₇H₁₃ClO₂
• Molecular Weight: 284.73692
• Mol File: 1378388-20-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.340±0.06 g/cm3 (20 ºC 760 Torr), Calc.*
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: GS-5818 interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: GS-5818 interMediate(1378388-20-5)
• EPA Substance Registry System: GS-5818 interMediate(1378388-20-5)

Safety Data

• Hazardous Substances Data: 1378388-20-5(Hazardous Substances Data)

Usage

General Description

The chemical GS-5818 intermediate, also known as GSK-1817919A, is a compound that serves as a key intermediate in the synthesis of GS-5818, an investigational antiviral drug for the treatment of respiratory syncytial virus (RSV). GS-5818 intermediate is a potent and selective inhibitor of the RSV fusion protein, which plays a critical role in the virus's ability to enter and infect human cells. GS-5818 interMediate has shown promising results in preclinical studies, demonstrating strong antiviral activity against RSV. Its synthesis and potential for further development as a treatment for RSV make GS-5818 intermediate an important compound in pharmaceutical research.

Upstream product

• 1993-03-9 o-fluorophenylboronic acid 
• 1072-85-1 o-fluorobromobenzene 
• 1380084-58-1 8-chloro-6H-benzo[c]chromene 
• 66192-24-3 2-bromo-5-chlorobenzyl bromide 
• 22009-38-7 7-hydroxy-1-tetralone 
• 1378388-19-2 7-(2-bromo-5-chlorobenzyloxy)-3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 1378390-29-4 3-(2-bromoacetyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 
• 1378390-35-2 (2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate 
• 1378390-69-2 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-methylpyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-38-8 3-(2-bromo-1-hydroxyethyl)-10,11-dihydro-5H-dibenzo[c,g]chromen-8(9H)-one 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

Preparation method of 10,11-dihydro-5H-benzo[d]naphtha[2,3-b]pyranone derivative

The invention discloses a preparation method of an anti-hepatitis C medicine Velpatasvir intermediate 10,11-dihydro-5H-benzo[d]naphtha[2,3-b]pyranone derivative which is 9-bromo-3-(2-bromoacetyl)-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one (V). The preparation method concretely comprises the following steps: carrying out coupling cyclization on a raw material 7-((2-bromo-5-chlorophenyl)oxo)-3,4-dihydronaphthalen-1(2H)-one under the action of a ligand and an alkali to synthesize 3-chloro-10,11-dihydro-5H-benzo[d]naphtho[2,3-b]pyran-8(9H)-one, substituting chlorine by using sodium cyanide to form cyanide, prearing an organic acid from the cyanide under the action of an alkali, processing the organic acid by a lithium methide reagent to obtain 3-acetyl-10,11-dihydro-5H-benzo[d]naphtho[2,3-b] ]pyran-8(9H)-one, and carrying out a two-step bromination reaction to obtain the anti-hepatitis C medicine Velpatasvir intermediate. The method provides a brand new synthesis route of the anti-hepatitis C medicine Velpatasvir intermediate, and has the advantages of easily controlled reaction steps, and realization of stable industrial production preparation.

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.